持续输注血管升压药期间脱离有创机械通气
该回顾性队列研究纳入Calgary ICU中接受有创机械通气并尝试拔管的成人患者,比较拔管时仍用血管升压药与已停用者的结局。总体拔管时用升压药与再插管风险无显著关联,但高剂量升压药拔管再插管风险增加,低剂量升压药拔管死亡更低且ICU住院更短。
要点
- 拔管时总体使用血管升压药与96小时内再插管风险无显著增加。
- 高剂量升压药(>0.1 μg/kg/min)拔管与再插管风险增加相关。
- 低剂量升压药(⩽0.1 μg/kg/min)拔管与更低死亡和更短ICU住院相关。
核心结论
- 拔管时使用高剂量而非低剂量血管升压药与再插管风险增加相关。
- 总体拔管时使用血管升压药与再插管风险无显著关联,但死亡和出院时间增加。
研究设计与样本
- 回顾性队列研究,纳入Calgary ICU接受血管升压药和有创机械通气并尝试拔管的成人患者。
- 共6140例,721例(11.7%)拔管时仍用血管升压药,5419例(88.3%)已停用。
- 主要暴露为拔管时继续使用血管升压药,主要结局为96小时内再插管。
主要发现
- 总体拔管时用升压药与再插管风险无显著关联(SHR 1.81,95%CI 0.91-3.61,P=0.09)。
- 总体拔管时用升压药与死亡风险增加(HR 1.22,95%CI 1.02-1.47,P=0.03)和出院时间延长(SHR 0.78,95%CI 0.68-0.91,P<0.01)相关。
- 高剂量升压药(>0.1 μg/kg/min)拔管与再插管风险增加相关(SHR 2.25,95%CI 1.01-4.98,P=0.046)。
- 低剂量升压药(⩽0.1 μg/kg/min)拔管与更低死亡(HR 0.69,95%CI 0.51-0.91,P=0.01)和更短ICU住院(SHR 1.34,95%CI 1.09-1.65,P=0.01)相关,再插管和医院住院无差异。
临床怎么用
- 拔管决策可结合血管升压药剂量评估,高剂量(>0.1 μg/kg/min)时需谨慎。
- 低剂量(⩽0.1 μg/kg/min)升压药期间拔管可能与更优结局相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Weaning protocols for discontinuation of invasive mechanical ventilation often mandate resolution of shock. Whether extubation while receiving vasopressors is associated with harm is uncertain. Objectives: To examine whether extubation while still receiving vasopressors is associated with worse outcomes. Methods: We performed a retrospective cohort study of adults in Calgary ICUs who received vasopressors with invasive mechanical ventilation and an extubation attempt. The primary exposure was continued vasopressor use at extubation. The primary outcome was reintubation within 96 hours. Secondary outcomes included in-hospital mortality and ICU/hospital length of stay (LOS). We assessed associations of vasopressor use at extubation with outcomes using multivariable competing-risk (reintubation/LOS) and Cox proportional-hazards (mortality) models. Measurements and Main Results: Of 6,140 patients who received invasive mechanical ventilation while on vasopressors, 721 (11.7%) were extubated while receiving vasopressors, and 5,419 (88.3%) after discontinuation. Extubation on vasopressors was not, in aggregate, significantly associated with an increased hazard of reintubation (subhazard ratio [SHR], 1.81 [95% confidence interval, 0.91-3.61]; P = 0.09). Both mortality (hazard ratio, 1.22 [1.02-1.47]; P = 0.03) and time to hospital discharge (SHR for remaining hospitalized, 0.78 [0.68-0.91]; P < 0.01) were increased. Extubation on high-dose vasopressors (>0.1 μg/kg/min) was associated with a greater hazard of reintubation (SHR, 2.25 [1.01-4.98]; P = 0.046) compared with extubation after vasopressor discontinuation. Meanwhile, extubation on low-dose vasopressors (⩽0.1 μg/kg/min) was associated with a lower mortality (hazard ratio, 0.69 [0.51-0.91]; P = 0.01) and a shorter ICU LOS (SHR, 1.34 [1.09-1.65]; P = 0.01), but no difference in reintubation or hospital LOS as compared with those weaned off vasopressors. Conclusions: Extubation while receiving high-dose but not low-dose vasopressors was associated with an increased risk of reintubation.
引用
- Zarrabian B, Wunsch H, Stelfox HT, et al. Liberation from Invasive Mechanical Ventilation with Continued Receipt of Vasopressor Infusions. Am J Respir Crit Care Med. 2022. PMID: 35107416. doi:10.1164/rccm.202108-2004OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。